ETF · ARK
0CQL ARK Genomic Revolution ETF
ISIN US00214Q3020London Stock Exchange: 0CQLARK Invest LLC
- Healthcare
- ETF
- Distributing
Latest close
LSE$53.45
on
- Ongoing charge
- 0.75% a year
- Fund size
- £1.3bn
Source: TradingView, as of , at least 15 min delayed
At a glance
As of 02/10/2026, 0CQL (ARK Genomic Revolution ETF, ISIN US00214Q3020) closed at $53.45 on the London Stock Exchange. Its ongoing charge is 0.75% a year (about £75 on £10,000). Over the five years to 02/10/2026 its total return was −26.5%, or −42.5% after UK CPIH inflation.
Past returns
- 1 year to 02/10/2026
- +88.2%
- +82.3% after inflation (UK CPIH)
- 3 years to 02/10/2026
- +84.7%
- +66.6% after inflation (UK CPIH)
- 5 years to 02/10/2026
- −26.5%
- −42.5% after inflation (UK CPIH)
£1,000 put in five years ago would have been worth about £735 on 02/10/2026 — about £575 in today’s spending power, once price rises are taken out. Past performance is not a guide to future returns.
Returns: TradingView (delayed data). Inflation: ONS CPIH, latest month published.
How we work it out:ReturnsReturns after inflationTotal returnReal returnCPIH
Calendar-year and 12-month returns
Calendar-year returns of ARK Genomic Revolution ETF in pounds (price only, income paid out not included): 2021 −39.1%, 2022 −50.3%, 2023 +12.2%, 2024 −25.4%, 2025 +15.8%; 2026 to 02/10/2026 +81.9%. Returns of ARK Genomic Revolution ETF in pounds (price only, income paid out not included) over the 12 months to 30/09/2026: +107.4%; to 30/09/2025: +3.5%; to 30/09/2024: −14.8%; to 30/09/2023: −26.2%; to 30/09/2022: −47.1%.
| Year | Return | After inflation | Return shown as a bar |
|---|---|---|---|
| to | +81.9% | +76.9% | |
| +15.8% | +11.8% | ||
| −25.4% | −28.0% | ||
| +12.2% | +7.7% | ||
| −50.3% | −54.5% | ||
| −39.1% | −41.9% |
| 12 months to | Return | After inflation |
|---|---|---|
| from | +107.4% | Not available |
| from | +3.5% | −0.6% |
| from | −14.8% | −16.9% |
| from | −26.2% | −30.6% |
| from | −47.1% | −51.3% |
Source: Fundology, from recorded closes and the data vendor’s weekly price history, as of , inflation: ONS CPIH
How we work it out:Calendar-year returnsWhat a calendar-year return isAccumulating and distributing
Risk: volatility and largest fall
Volatility (annualised)
41.5%over 5 years
| 1 year | 41.8% |
|---|---|
| 3 years | 41.5% |
| 5 years | 41.5% |
Annualised from weekly returns. Higher means bumpier.
- Largest fall since October 2021
- −75.6%
- From to
- Lowest 12-month return
- −61.5%
- 12 months to
- Highest 12-month return
- +101.2%
- 12 months to
- Below its highest weekly close since October 2021
- 31.0%
- High of , latest
In words: Volatility of ARK Genomic Revolution ETF in pounds, annualised from weekly returns to 02/10/2026: 41.8% over 1 year, 41.5% over 3 years, 41.5% over 5 years. Largest fall in the price of ARK Genomic Revolution ETF since October 2021, in pounds: −75.6% from 05/11/2021 to 04/04/2025. The lowest 12-month return of ARK Genomic Revolution ETF in pounds (price only, income paid out not included) since December 2020 was −61.5% (12 months to 17/06/2022); the highest was +101.2% (12 months to 25/09/2026). On 02/10/2026 the price of ARK Genomic Revolution ETF was 31.0% below its highest weekly close since October 2021 (05/11/2021), in pounds.
Source: Fundology, from recorded closes and the data vendor’s weekly price history, as of , price only — income paid out is not included
How we work it out:Risk figuresFallsVolatilityLargest fall
Charges compared with similar funds
- Ongoing charge
- 0.75%
- a year
- On £10,000
- £75
- a year, roughly
- Over five years
- £369
- of £10,000, before growth
- 17 charge less
- 0 the same
- 1 charge more
Ongoing charge of ARK Genomic Revolution ETF 0.75% a year, as of 03/10/2026: 1 of the 18 other healthcare funds charge more, 0 the same and 17 less (share classes counted once).
Source: Fund ongoing charges via TradingView, as of
A lower charge is not a promise of a higher return: what the fund holds matters more. Charges are the fund’s own published ongoing charges figure.
Read more:Ongoing charge (OCF)OCF and TERFee dragHow charges add up
In plain English
ARK Genomic Revolution ETF is an exchange-traded fund (ETF) from ARK, launched in 2014.
It tracks the No Underlying Index.
You buy and sell it through a share-dealing account or platform during stock-market hours, like a share.
Its ongoing charge is 0.75% a year — about £75 a year on every £10,000 invested, taken from the fund's value rather than billed to you.
Income from its investments is paid out to holders as cash, usually a few times a year.
Healthcare: Pharmaceutical, biotech and medical-equipment companies.
Key facts
- Ticker
- 0CQL
- ISIN
- US00214Q3020
- Provider
- ARK
- Tracks
- No index — the manager chooses the holdings
- Structure
- ETF
- An exchange-traded fund: bought and sold on the stock exchange through the day, like a share.
- Income
- Distributing, paid annual
- Income is paid out to holders as cash, usually a few times a year.
- Ongoing charge
- 0.75% a year · about £75 on £10,000
- Fund size
- £1.3bn
- Launched
- Domicile
- United States
- Currency hedged
- No
- Price currency
- USD
- Category
- Healthcare
Price chart
Since 31/07/2026, the closing price went from $38.09 on 31/07/2026 to $53.45 on 02/10/2026 (+40.3%). The lowest close shown was $38.09 on 31/07/2026 and the highest $53.45 on 02/10/2026.
Chart: closing prices we have recorded since 31/07/2026. Price only — income paid out is not included, so the line can end below the total return above.
Source: TradingView, as of , at least 15 min delayed
Five years of prices, and after inflation
11 weekly closes, from 31/07/2026 to 05/10/2026. The same history in October 2026 pounds, adjusted with ONS CPIH inflation.
Create a free account to see the 5-year price chart and the after-inflation chart
Sign-up takes an email address. There is no card to enter and nothing to pay.
How we work it out:Prices and returnsNAV and price
Risk and return in depth
Sharpe, Sortino and Calmar ratios
Sharpe, Sortino and Calmar ratios over 1, 3 and 5 years, from weekly returns in pounds.
With a free accountRolling returns
The full range of 247 rolling 12-month returns since December 2020, and of 145 rolling three-year returns, in pounds, with how often they were above zero.
With a free accountLargest falls and recoveries
The largest fall since October 2021, in pounds, with how many weeks it took to reach its low and to recover.
With a free account
Create a free account to see the risk ratios, every rolling return and each large fall and its recovery
Sign-up takes an email address. There is no card to enter and nothing to pay.
Moves compared with a similar fund
Correlation and beta of weekly returns in pounds against iShares Core MSCI World UCITS ETF, over the three years to 05/10/2026 (151 weeks).
Pro
Pro — currently by invitation
Pro includes moves against a comparable fund
Pro is open by invitation while it is being built. There is nothing to buy. To ask about access, email [email protected].
Questions people ask
What is the ongoing charge of 0CQL?
The ongoing charge of 0CQL is 0.75% a year — about £75 a year on every £10,000 invested, taken from the fund’s value rather than billed to you. Platform and dealing fees are charged separately. Ongoing charge of ARK Genomic Revolution ETF 0.75% a year, as of 03/10/2026: 1 of the 18 other healthcare funds charge more, 0 the same and 17 less (share classes counted once).
Is 0CQL accumulating or distributing?
0CQL is distributing: income is paid out to holders as cash, usually a few times a year. It pays out annual.
What is the ISIN of 0CQL?
The ISIN of 0CQL is US00214Q3020. An ISIN identifies one exact share class of a fund; 0CQL is its ticker on the London Stock Exchange.
What were 0CQL’s returns in each of the last five years?
Calendar-year returns of 0CQL in pounds (price only, income paid out not included): 2021 −39.1%, 2022 −50.3%, 2023 +12.2%, 2024 −25.4%, 2025 +15.8%; 2026 to 02/10/2026 +81.9%. Past performance is not a guide to future returns.
How has 0CQL done after inflation?
Over the five years to 02/10/2026 0CQL’s total return was −26.5%, or −42.5% after UK CPIH inflation. Past performance is not a guide to future returns.
Similar funds
- XWHSXtrackers MSCI World Health Care UCITS ETF0.25% a year · £2.3bn
- IHCUiShares S&P 500 Health Care Sector UCITS ETF0.15% a year · £1.8bn
- XSHCXtrackers MSCI USA Health Care UCITS ETF0.12% a year · £550m
- 0DW6Amundi MSCI World Health Care UCITS ETF EUR ACC0.30% a year · £541m
- ESIHiShares MSCIEurope Health Care Sector UCITS ETF AccumEUR0.18% a year · £541m
- CH5Amundi STOXX Europe 600 Healthcare UCITS ETF -Acc- Capitalisation0.30% a year · £537m
- AGESiShares Ageing Population UCITS ETF0.40% a year · £503m
- 0MP1iShares STOXX Europe 600 Health Care UCITS ETF (DE)0.46% a year · £441m
Sources and dates
- Prices
- London Stock Exchange closes via TradingView, at least 15 minutes delayed, latest
- Returns
- TradingView reported returns (net asset value with income reinvested where available)
- Calendar years, risk
- Fundology, from recorded closes (weekly history from the data vendor where our record is short)
- Inflation
- ONS CPIH, latest month used August 2026
- Charges
- The fund’s ongoing charges figure, via TradingView
- Identity
- FCA Financial Instruments Reference Data System (FIRDS) and the issuer
- Fund size
- TradingView, converted to pounds at the latest ECB reference rate
Methodology:Data sourcesReturnsCategoriesAll methods
A machine-readable copy of this page: Markdown.